Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation

Abstract

CD56 expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia and multidrug resistance, but its clinical and prognostic significance has not been clearly identified. This study examined CD56 expression in 37 adult de novo AML patients with t(8:21). CD56 was expressed in 25 cases (67.6%). Complete remission (CR) rates were similar in both groups (91.7% vs. 88.7%; P = 0.73), but the relapse rates differed considerably (60% vs. 25%; P = 0.02). The median duration of disease-free survival (DFS) was significantly shorter in the CD56+ (median, 12.2 ± 6.4 months) than in the CD56À group (median, not reached) (P = 0.02). In addition, the median duration of survival differed significantly in the CD56+ group (median, 14.9 ± 4.4 months) compared with the CD56À group (median, not reached) (P = 0.01). Of the fifteen transplanted patients who achieved CR, allogeneic HST was performed from their siblings. The median duration of DFS in the CD56+ patients was significantly shorter than the CD56À patients (median, 24.4 ± 4.5 months vs. median, not reached; P = 0.02). We concluded that CD56 expression correlates to a reduced DFS and survival for AML patients with t(8:21), including those patients who underwent transplantation. Am. J.

Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression

“…Moreover, both p48 and CD56 induce NF-B and bcl2L12 in AML cells and protect them from apoptosis, potentially explaining the correlation between CD56 expression and the poor response of CD56 ϩ AMLs to current treatments. 5,18 However, considering the broad spectrum of p48 targets, other mechanisms contributing to the aggressive phenotype of CD56 ϩ AMLs could be anticipated. Overexpression of macrophage colony-stimulating factor in t(8;21)(q22;q22) translocation-positive AMLs resulting from the interaction of wild-type RUNX1 with the RUNX1-ETO fusion protein 19 is one example.…”

Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways

“…The final concentration of DMSO was less than 0.1%. N-acetyl-L-cysteine (NAC, antioxidant, Sigma- [20] 45, X, -X, t(8;21)(q22;q22) [20] 46, XX, t(9;22)(q34;q11) [60] 47, XX, t(10;11)(p12;q23)+mar [7] /46, XX [3] 46, XX, t(9;11)(p12;q23) [20] 46, XX, N [20] No split phase 46, XY, t(9;22)(q34;q11) [38] 46, XX [20] 46, XX, del(2)(p11), del(3)(p12), del(3)(p26), del(3)(q13), del(4)(q31), del(6)(p23), del(7)(q22q34), -10, del(12) (p12), del(13)(q12q14), +15, -16, -21, +mar[cp10] 46, XY [12] www.nature.com/aps Xiong XX et al Acta Pharmacologica Sinica npg Aldrich, St Louis, MI, USA) was used at 3 mmol/L, whereas SB203580 (P38 pathway-specific inhibitor, Cell Signaling Technology, Danvers, MA, USA) and SP600125 (JNK pathwayspecific inhibitor, Cell Signaling Technology) were used at 10 µmol/L. NAC, SB203580, and SP600125 were added 1 h before PL-treatment.…”

“…CML, which accounts for approximately 15%-20% of all leukemias arising in adulthood, is characterized by the overproduction and accumulation of mature but functionally impaired myeloid cells and carries the risk of progressing into an accelerated phase and a blast crisis that are refractory to the current treatments [2] . Chemotherapy plus hematopoietic stem-cell transplantation (SCT) have greatly improved the overall survival time of AML patients [3,4] ; however, at this time, approximately 30%-40% of AML patients do not have access to SCT or are resistant to the current chemotherapeutics [5,6] . Moreover, high-dose chemotherapy is highly toxic and causes severe side effects, such as skin rash, edema, muscular cramps or pustular eruptionswww.chinaphar.com Xiong XX et al Acta Pharmacologica Sinica npg traditional Ayurvedic medicine to treat gastrointestinal and respiratory diseases for a thousand years [8] .…”

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

“…LSC are thought to be quiescent and therefore to confer chemotherapy resistence (Saito et al, 2010). Expression of CD34 (Lapidot et al, 1994), CD32, CD25 (Saito et al, 2010), CD47 ), CD96 (Hosen et al, 2007), CD123 (Will & Steidl, 2010), and CD56 (Young et al, 1999) have been associated with a stem cell phenotype and frequency of fluorescent-activated cell sorting (FACS)-positive expression of CD34 Rockova et al, 2011), CD25 (Terwijn et al, 2009;Gonen et al, 2012), CD47 ) and CD56 (Raspadori et al, 2001) on leukaemic blasts are associated with adverse prognosis, the latter especially pronounced for patients with t (8;21) (Yang et al, 2007;Iriyama et al, 2013).…”